SEVERAL causes for the reperfusion injury of the heart have been described, including the production of free radicals' or the retention of platelets2 and polymorphonuclear neutrophils (PMNS)'"~* in the coronary system. Close interaction of PMNs and endothelial cells can be mediated by two different pathways: capillary plugging, as a nonspecific physical process ensuing from narrowed capillary lumina after edema formation or reduced leukocyte ela~ticity,~~' and specific interaction of adhesion molecules, such as CDl lb/CD18 with intercellular adhesion molecule 1. ' The destructive potential of adherent and activated PMNs on the integrity of the endothelial barrier is mediated by their ability to form reactive oxygen species and to liberate proteolytic enzymes. ' In the clinical situation of cardiopulmonary bypass, activation of neutrophils is observed.y7."' In the following reperfusion situation, these activated neutrophils can further aggravate the reperfusion injury. Kowalski et al." demonstrated that sevoflurane, isoflurane, and halothane in concentrations of 1 and 2 minimum alveolar concentrations (MACs) each reduced PMN adhesion in the reperfused, nonworking heart. In that study, neither the effect of reduced PMN adhesion on myocardial performance after ischemia nor the underlying mechanism for reduced neutrophil adhesion were analyzed. Thus, we examined the effects of sevoflurane and isoflurane in the clinically relevant concentrations of 0.5 and 1 MAC on PMN adhesion in the reperfused myocardium, using a standardized model of isolated guinea pig hearts, performing pressure-volume work, and washed human PMN. Additionally, PMNs were immunocytometrically characterized (expression of CD11 b) before and after 
Heart Preparation
The care of the animals was in full accordance with German animal-protection laws, and the experiments were officially approved by the institutional animal care committee.
Hearts were isolated from male guinea pigs (body weight 200 -300 g) following cervical dislocation, without use of any anticoagulants or anesthetics. After median thoracotomy the beating hearts were arrested immediately by superfusion with ice-cold isotonic saline. The ascending aorta was cannulated and the hearts were excised. The isolated organs were perfused at 37°C using a modified Krebs-Henseleit buffer containing, in millimoles per liter, NaCl 126, NaHCO The perfusion pressure in the nonworking mode (Langendorff mode) was continuously recorded in the aortic cannula with a pressure transducer (FMI GmbH, Egelsbach, Germany), and aortic and coronary flows were monitored with an ultrasonic flow meter (Transsonic Systems, Ithaca, Ny). Heart rate was derived from the phasic perfusion pressure signal.
Preparation of PMNs
The use of human PMNs instead of guinea pig PMNs in our xenogenic model offered several advantages: Using human blood, we were able to reduce substantially the number of animals needed for the experiments, as no blood-donor animals were required. Additionally, a monoclonal antibody against the integrin CDl l b is available for human PMNs but not for those of guinea pigs. Furthermore, in previous experiments we have found that PMNs from guinea pigs and humans show a quanti- tatively similar degree of adhesion in our model under both preischemic and postischemic conditions. PMNs were isolated from fresh venous blood of healthy volunteers, as described in detail previously. l4 Briefly, the blood was anticoagulated with 0.1% EDTA and centrifuged at 380g for 10 min. Plasma was discarded and the buffy coat carefully collected. The buffy coat was incubated with an iron-tagged monoclonal antibody against CD15 (Miltenyi, Bergisch Galdbach, Germany), an epitope specific for neutrophils, at 4°C for 15 min, and subsequently passed through a magnetized column. The column was flushed with phosphate-buffered saline (pH 7.4) to wash away unlabeled cells and, after removing the column from the magnetic field, PMNs were eluted with phosphate-buffered saline. The eluent was centrifuged at 380g for 10 min, and the resulting cell pellet resuspended in Tyrode's solution, counted, and adjusted to a final cell count of 3 x 10' cells/ml Tyrode's solution. The total time of preparation was less than 1 h.
Experimental Protocol f o r Working Hearts
The perfusion protocol is outlined in figure 1 . Initially, hearts performed pressure-volume work (W,) for 20 min. During this work phase the mean aortic pressure and the left atrial filling pressure were held constant, whereas the coronary flow was autoregulated by the hearts. Thereafter, perfusion of the hearts was changed to a nonworking, constant coronary flow mode, during which-in contrast to the work phases-coronary perfusion pressure was variable. A coronary flow of 5 ml/min was established for 15 min. After that, hearts were subjected to global no-flow ischemia for 15 min. Myocardial reperfusion was established at constant coronary flow of 5 ml/min for the next 20 min, whereafter work (w,) was performed again (20 min) under conditions identical to those of W,. To rule out temperature effects in the nonworking Langendorff phases, hearts were immersed in 37°C Tyrode's solution.
Sevoflurane or isoflurane were added in concentrations of 0.5 MAC or 1 MAC (corresponding to 1 or 2 vol% ~evoflurane'~ and 0.6 or 1.2 VOM isofluraneI6, respectively) to the oxygen-carbon dioxide gas mixture used to equilibrate a separate perfusate reservoir for the nonworking mode. This perfusate was used 15 min preischemically and for the first 5 min of the reperfusion phase.
The addition of anesthetics to the perfusate was achieved by means of a calibrated vaporizer (Driger, Lubeck, Germany), as described previously, l 7 and was monitored by piezo electric gas detectors (Drager). To ensure equilibration of volatile anesthetics with the liquid phase, application of anesthetics with the gas phase to the perfusate began 30 min before its use. To exclude negative inotropic effects of sevoflurane and isoflurane on cardiac performance during W, and W,, no anesthetics were applied during the work phases. To speed up washout of volatile anesthetics from the heart until W,, an anesthetic-free, oxygenated perfusate was used after the 5th min of reperfusion.
In the second min of reperfusion an optional 1-ml bolus of PMNs (3 x 10") suspended in Tyrode's solution was applied over 1 min into the coronary system via the aortic cannula with an infusion pump. To determine the rate of basal adhesion under nonischemic conditions, in one group of hearts the PMN bolus was applied in the 10th min of preischemic, volume-constant perfusion (see below). Hearts were randomly allocated to the following experimental groups: At the end of W, and W, coronary flow, aortic flow, spontaneous heart rate, and ejection time of stroke volume were measured. External heart work (EHW) was calculated from these variables as the sum of pressurevolume work and acceleration work.'2 Because preload and afterload were held constant during phases of work, changes in cardiac performance were reflected largely as alterations in cardiac output. Recovery of EHW was defined as the ratio of the values obtained in W, and W, and expressed as a percentage.
Adhesion Measurements
Sequestration of PMNs into the coronary system was determined from the arteriovenous difference in absolute PMN count. Immediately before each intracoronary application of a bolus of PMNs, a test bolus of equal volume and duration (1 ml in 1 min) was sampled to determine the number of cells actually leaving the application syringe (PMN input). To quantify the number of PMNs leaving the coronaries (PMN output), coronary effluent was collected continuously during the minute of bolus application and in the following minute. Pilot studies had shown that only a negligible number of the applied PMNs (< 1%) emerged after such a 120-s Sampling period. The test bolus and the coronary effluent were sampled into ice-cold 10% formaldehyde solution to fix cells for counting and flow cytometric analysis. The percentage of PMNs adherent to the endothelium was calculated as follows:
Flow Cytometry Formalin-fixed PMNs of the test bolus and of the coronary effluent were analyzed in a FACScan flow cytometer (Becton Dickinson, San Jose, CA) for the expression of the integrin subunit CDllb using a fluorescent dyelabeled monoclonal antibody (Serotec, Oxford, UK). In general, samples of the test boli and the coronary effluent fixed in formalin were centrifuged at 1,2009 for 15 min and the supernatant was discarded. PMNs were resuspended in 100 pl Cellwash (a phosphate-buffered saline solution; Becton Dickinson) and incubated 15 min after addition of 5 pl of the monoclonal antibody. Thereafter, 1 ml of Cellwash was added for dilution of the antibody and PMNs were centrifuged again at 1,200s for 15 min. The pellet was resuspended in 500 pl Cellwash and the cells were immediately analyzed in the flow cytometer for relative mean particle fluorescence intensity and forward scatter and sideward scatter distribution. Light is scattered as a cell passes through the laser beam. Forward scattered light is a measure of particle size and shape and is normally measured in the laser beam axis. Sideward scattered light is related to the granularity of the cells and measured at a 90-degree angle to the laser axis. To compensate for any day-to-day variation in instrument response, nonspecific relative mean particle fluorescence intensity of the corresponding negative control was subtracted from values measured with specific antibodies.
Statistical Analysis
Comparison of several groups was performed using one-way analysis of variance and the Student-NewmanKeul's test. Differences between data were considered significant at P < 0.05. volatile anesthetics, even when applied at a concentration of 2 MAC."
Results

Adhesion of PMN
Coronary Perfusion Pressure
The time course of the coronary perfusion pressure during preischemic and postischemic volume-constant perfitsion is outlined in table 1. No overt decrease of coronary perfusion pressure and thereby of coronary resistence (constant flow) was observed in the presence of the volatile anesthetics at the concentrations employed here. Coronary perfusion pressure did not change after application of the PMN bolus in the second min of reperfusion, and, thus, capillary plugging can be ruled out as a major cause of PMN sequestration. During early postischemic reperfusion there was always some reactive dilatation (decrease in coronary perfusion pressure). In the course of reperfusion coronary perfusion pressure rose continuously, exceeding preischemic levels after 15 niin in all groups. However, no significant differences were detectable between groups at any time.
Hemodynamic Parameters and Recovery of EHW
The hemodynamic data of the working hearts are listed in detail in table 2 . There were no significant differences of any of the measured parameters between groups in w,. Coronary flow was consistently lower in W, than in W,, whereas heart rate only tended to fall somewhat. The greatest effects, however, were seen for aortic flow and EHW. For both parameters, the values of the ischemia plus PMN postischemic group were significantly lower in W, compared with all other groups. The volatile anesthetics had no influence by themselves but served to overcome the postischemic losses of function induced by PMN applied in the second min of reperfusion.
The postischemic recovery of EHW is illustrated in figure 3 . EHW of time-control hearts, i.e., hearts that had not been subjected to ischemia, proved to be stable and in W , averaged about 95% of the value in W,. EHW of ischemia-control hearts in W, was reduced to about 60% ( fig. 3A) . Neither the application of 1 MAC isoflurane or sevoflurane in the absence of PMNs nor the preischemic infusion of PMNs had an additional influence on functional recovery ( fig. 3B ). In contrast, application of PMNs in the second min of reperfusion significantly reduced recovery of EHW to a mere 20%: a loss of about 40% versus the ischemia-control group and of 75% in comparison with the time-control group. Application of sevoflurane and isoflurane at concentrations of both 0 . 5 and 1 MAC prevented the deterioration of heart performance otherwise seen after PMN application ( fig. 3B ).
Immunocytnmetric Characterization of PMN
The relative inimunofluorescence intensity of CDI l b before coronary passage (test bolus) ranged between 10 and 22 relative units but did not significantly differ between the groups. Because the expression of CDllb showed a marked variability between different cell preparations already in the test boli, the individual percentage change of CDl1 b after coronary passage was calculated for each experiment. That relative increase is depicted for all groups in figure 4 . Whereas preischemic infusion of PMNs did not result in an activation, postischemic application of PMNs led to a significant increase of CD1 l b expression (fig. 4 ) . Interestingly, application of sevoflurane and isoflurane significantly inhibited the rise in CDl l b expression during postischemic coronary passage, both at 0 . 5 and 1 MAC concentration.
The forward scatter of PMNs, which is a measure of shape and volumes change of cells," increased in all groups during coronary passage, although the sideward scatter, which is a parameter of cellular granule content,18 decreased (table 3) . Thus, application of volatile anesthetics did not influence the average shape change and secretion of granula of PMNs seen in PMNs collected after coronary passage.
Discussion
As previously demonstrated, volatile anesthetics did not influence the basal adhesion of PMNs under nonischemic conditions, even at a concentration of 2 MAC." In the reperfusion phase adhesion was almost doubled, but application of sevoflurane or isoflurane at concentrations of 0.5 and 1 MAC equally reduced postischemic PMN sequestration to or near to basal levels. Application of 2 MAC had no further effect.' Obviously, in the range investigated, there was no direct dose-response relationship for the applied concentrations of anesthetics and PMN adhesion, we rather observed an all-or-nothing relation. Thus, both sevoflurane and isoflurane selectively reduce postischemic PMN adhesion at concentrations relevant for the clinical situation.
Reduced PMN sequestration in the reperfusion phase was associated with significantly improved recovery of EHW in comparison to the ischemia plus PMNs group. Our finding that reduced neutrophil adhesion occurs in parallel to improved heart recovery after ischemia is in accordance to results obtained by others.
Cardioprotective properties of sevoflurane and isoflurane have been described by several groups, including metaor, additionally, functional improvement after ischemiaz3-26, although without considering involvement of PMN. Our finding that 1 MAC sevoflurdne or isoflurane in the absence of PMNs did not improve recovery of EHW in comparison to the ischemia-control group does not exclude a direct cardioprotective effect of volatile anesthetics, as described by others. The experimental setup and protocol (duration of ischemia, mode of reperfusion, species, etc.) may have an important influence on the direct cardioprotective properties of volatile anesthetics.
The inhibitory effect of volatile anesthetics on PMN adhesion could be mediated by "nonspecific" effects on the myocardium or the microvasculature or by "specific" effects on the integrin-mediated adhesion event. As an example of the former, sevoflurane and isoflurane might influence the ischemic alterations of the heart and thereby protect the myocardium in the reperfusion phase. Two facts argue against this possibility. First, in previous studies we demonstrated that sevoflurane and isoflurane had no impact on the production of lactate by isolated hearts after ischemia.' 'J' Second, in the present study no increased recovery of heart function was detectable under control conditions (no PMN infusion) in the presence of 1 MAC of sevoflurane or isoflurane in comparison with the ischemia-control group, as one would have to expect for an ischemia-mitigating effect of volatile anesthetics. CDllb is expressed on the cell surface of PMNs and is up-regulated after activation. It forms a heterodimer with CD18, and this complex binds to intercellular adhesion molecule 1 which is expressed on the endothelium, thereby mediating the sticking of activated PMNs.*' Coap plication of PMNs and a monoclonal antibody against CD18 reduced PMN adhesion to about 10% under pre-and postischemic conditions in our model." Part of this remaining 
Experimental Group
10% of sequestered PMNs might be the consequence of mechanical trapping in the coronary system. However, the coronary perfusion pressure showed no increase after PMN application, unlike what has been observed after capillary plugging with 10-pm diameter micro sphere^.'^ Thus, formation of PMN aggregates and any substantial capillary plugging can be excluded in our experimental setting. Reduced mechanical trapping of PMNs caused by vasodilation of the microvasculature in the presence of volatile anesthetics as a relevant factor for the reduction of PMN adhesion can be also largely ruled out at 0.5 and 1 MAC (table 1) . For these reasons, the majority of PMNs, especially under postischemic conditions, probably become adherent as the result of specific, integrin-mediated inter- Coronary passage of PMNs induced a shape change (polarization) and a slight degranulation of PMNs'~ in all groups, including PMNs applied under preischemic conditions. For these changes, therefore, the coronary passage itself, but not reperfusion conditions, seems to suffice as trigger. Polarization and degranulation of PMN normally occur after their activation. In the ischemia plus PMNs postischemic group the most activated PMNs become stuck in the coronary system and therefore cannot be analyzed in the coronary effluent. Accordingly, PMNs applied postischemically show about the same extent of polarization and degranulation after coronary passage as those applied preischemically. This is corroborated by the fact that PMNs pretreated with anti-CD18, which inhibits adhesion of the activated PMNs, show a significantly increased degranulation after coronary passage." In contrast, the additional PMN emerging from hearts receiving the volatile anesthetics were not activated to any greater extent than the preischemic controls. Thus, one may conclude that volatile anesthetics mitigate PMN adhesion. Significantly increased expression Of 'Dl lb after coronary passage was only observed when PMNs were applied in the postisch- i
